<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for Novo Nordisk A/S’s (NYSE: NVO) Ozempic’s new dose of 2.0 mg. Ozempic (semaglutide) is currently approved in the EU in 0.5 mg and 1.0 mg doses for type 2 diabetes in adults.
...read full article on Benzinga
